{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T13:26:10Z","timestamp":1787664370526,"version":"build-2736575974"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T00:00:00Z","timestamp":1757635200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002347","name":"BMBF Bonn","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thegreenjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.radonc.2025.111122","type":"journal-article","created":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T22:22:03Z","timestamp":1757197323000},"page":"111122","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Impact of radiation dose on immune cells (EDIC) on oncologic outcome in small cell lung cancer (SCLC)"],"prefix":"10.1016","volume":"212","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-5422-4145","authenticated-orcid":false,"given":"Hannah Sophie","family":"Penzl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David Alexander","family":"Ziegler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus Anton","family":"Schirmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0851-9176","authenticated-orcid":false,"given":"Jona","family":"Bensberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8655-3172","authenticated-orcid":false,"given":"Sonia","family":"Ziegler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedikt","family":"Kieslich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla Marie","family":"Zwerenz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Hille","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leif Hendrik","family":"Dr\u00f6ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Leu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2599-6196","authenticated-orcid":false,"given":"Manuel","family":"Guhlich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"von Diest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura Anna","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahalia Zoe","family":"Anczykowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2579-0171","authenticated-orcid":false,"given":"Tobias","family":"Overbeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"von Hammerstein-Equord","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friederike","family":"Braulke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-7018-2856","authenticated-orcid":false,"given":"Stefan","family":"Rieken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1355-7882","authenticated-orcid":false,"given":"Rami","family":"El Shafie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.radonc.2025.111122_b0005","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.radonc.2025.111122_b0010","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","article-title":"First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer","volume":"379","author":"Horn","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.radonc.2025.111122_b0015","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1016\/S0140-6736(19)32222-6","article-title":"Durvalumab plus platinum\u2013etoposide versus platinum\u2013etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial","volume":"394","author":"Paz-Ares","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.radonc.2025.111122_b0020","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/S1470-2045(17)30318-2","article-title":"Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised","volume":"18","author":"Faivre-Finn","year":"2017","journal-title":"Superiority Trial Lancet Oncol"},{"key":"10.1016\/j.radonc.2025.111122_b0025","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.annonc.2021.03.207","article-title":"Small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Dingemans","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.radonc.2025.111122_b0030","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1056\/NEJMoa2404873","article-title":"Durvalumab after Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer","volume":"391","author":"Cheng","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.radonc.2025.111122_b0035","doi-asserted-by":"crossref","first-page":"3199","DOI":"10.4049\/jimmunol.139.10.3199","article-title":"Gene induction by gamma-irradiation leads to DNA fragmentation in lymphocytes","volume":"139","author":"Sellins","year":"1987","journal-title":"J Immunol"},{"key":"10.1016\/j.radonc.2025.111122_b0040","doi-asserted-by":"crossref","first-page":"224","DOI":"10.2307\/3577549","article-title":"Radiosensitivity of CD4 or CD8 positive human T-lymphocytes by an in vitro colony formation assay","volume":"123","author":"Nakamura","year":"1990","journal-title":"Radiat Res"},{"key":"10.1016\/j.radonc.2025.111122_b0045","doi-asserted-by":"crossref","DOI":"10.4161\/onci.28518","article-title":"Radiation fosters dose-dependent and chemotherapy-induced immunogenic cell death","volume":"3","author":"Golden","year":"2014","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.radonc.2025.111122_b0050","first-page":"187","volume":"16","author":"Bradley","year":"2015","journal-title":"LancetOncol"},{"key":"10.1016\/j.radonc.2025.111122_b0055","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S1470-2045(20)30013-9","article-title":"Imaging-based target volume reduction in chemoradiotherapy for locally advanced non-small-cell lung cancer (PET-Plan): a multicentre, open-label, randomised, controlled trial","volume":"21","author":"Nestle","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2025.111122_b0060","doi-asserted-by":"crossref","first-page":"6193","DOI":"10.3390\/cancers13246193","article-title":"Higher radiation dose to the immune cells correlates with worse tumor control and overall survival in patients with stage III NSCLC: a secondary analysis of RTOG0617","volume":"13","author":"Jin","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.radonc.2025.111122_b0065","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.radonc.2021.06.020","article-title":"Impact of effective dose to immune cells (EDIC) on lymphocyte nadir and survival in limited-stage SCLC","volume":"162","author":"Yu","year":"2021","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2025.111122_b0070","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/j.adro.2020.03.021","article-title":"Lymphopenia and radiation dose to circulating lymphocytes with neoadjuvant chemoradiation in esophageal squamous cell carcinoma","volume":"5","author":"So","year":"2020","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.radonc.2025.111122_b0075","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.radonc.2020.02.015","article-title":"The impact of the effective dose to immune cells on lymphopenia and survival of esophageal cancer after chemoradiotherapy","volume":"146","author":"Xu","year":"2020","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2025.111122_b0080","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.ijrobp.2019.05.064","article-title":"Impact of radiation dose to the host immune system on tumor control and survival for stage III non-small cell lung cancer treated with definitive radiation therapy","volume":"105","author":"Ladbury","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2025.111122_b0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2023.109804","article-title":"Impact of radiation dose to the immune system on disease progression and survival for early-stage non-small cell lung cancer treated with stereotactic body radiation therapy","volume":"186","author":"Wang","year":"2023","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2025.111122_b0090","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.radonc.2021.03.026","article-title":"Is a higher estimated dose of radiation to immune cells predictive of survival in patients with locally advanced non-small cell lung cancer treated with thoracic radiotherapy?","volume":"159","author":"Yin","year":"2021","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2025.111122_b0095","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.radonc.2022.07.015","article-title":"Impact of radiation dose to the immune cells in unresectable or stage III non-small cell lung cancer in the durvalumab era","volume":"174","author":"McCall","year":"2022","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2025.111122_b0100","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.6004\/jnccn.2015.0151","article-title":"Survival in patients with severe lymphopenia following treatment with radiation and chemotherapy for newly diagnosed solid tumors","volume":"13","author":"Grossman","year":"2015","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.radonc.2025.111122_b0105","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/j.ijrobp.2024.08.013","article-title":"Concurrent Chemoradiation \u00b1 Atezolizumab (Atezo) in limited-stage small cell lung cancer (LS-SCLC): results of NRG Oncology\/Alliance LU005","volume":"120","author":"Higgins","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2025.111122_b0110","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1200\/JCO.20.01055","article-title":"Updated overall survival and PD-L1 subgroup analysis of patients with extensive-stage small-cell lung cancer treated with atezolizumab, carboplatin, and etoposide (IMpower133)","volume":"39","author":"Liu","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2025.111122_b0115","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.radonc.2020.07.012","article-title":"ESTRO ACROP guidelines for target volume definition in the thoracic radiation treatment of small cell lung cancer","volume":"152","author":"Le Pechoux","year":"2020","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2025.111122_b0120","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1016\/j.ijrobp.2009.06.017","article-title":"Stereotactic body radiation therapy for early-stage non\u2013small-cell lung cancer: the pattern of failure is distant","volume":"77","author":"Bradley","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2025.111122_b0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.102986","article-title":"LBA1 Durvalumab in combination with chemoradiotherapy for patients with unresectable stage III NSCLC: final results from PACIFIC-2","volume":"9","author":"Bradley","year":"2024","journal-title":"ESMO Open"},{"key":"10.1016\/j.radonc.2025.111122_b0130","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20170157","article-title":"Combining radiotherapy with immunotherapy: the past, the present and the future","volume":"90","author":"Van Limbergen","year":"2017","journal-title":"Br J Radiol"},{"key":"10.1016\/j.radonc.2025.111122_b0135","first-page":"450","article-title":"Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial","volume":"22","author":"Lee","year":"2021","journal-title":"LancetOncol"},{"key":"10.1016\/j.radonc.2025.111122_b0140","first-page":"572","article-title":"Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial","volume":"25","author":"Machiels","year":"2024","journal-title":"LancetOncol"},{"key":"10.1016\/j.radonc.2025.111122_b0145","doi-asserted-by":"crossref","first-page":"131","DOI":"10.3109\/02841868809090333","article-title":"The hazard of accelerated tumor clonogen repopulation during radiotherapy","volume":"27","author":"Withers","year":"1988","journal-title":"Acta Oncol"},{"key":"10.1016\/j.radonc.2025.111122_b0150","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.radonc.2022.01.032","article-title":"Once Daily (OD) versus Twice-Daily (BID) chemoradiation for limited stage small cell lung cancer (LS-SCLC): a meta-analysis of randomized clinical trials","volume":"173","author":"Viani","year":"2022","journal-title":"Radiother Oncol"}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814025046262?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814025046262?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T04:19:40Z","timestamp":1780114780000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167814025046262"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":30,"alternative-id":["S0167814025046262"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2025.111122","relation":{},"ISSN":["0167-8140"],"issn-type":[{"value":"0167-8140","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of radiation dose on immune cells (EDIC) on oncologic outcome in small cell lung cancer (SCLC)","name":"articletitle","label":"Article Title"},{"value":"Radiotherapy and Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radonc.2025.111122","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"111122"}}